Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF APRIL 17, 2010 FBO #3066
SOURCES SOUGHT

B -- HIV Incidence Assay Validation

Notice Date
4/15/2010
 
Notice Type
Sources Sought
 
NAICS
541990 — All Other Professional, Scientific, and Technical Services
 
Contracting Office
Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
 
ZIP Code
30341-4146
 
Solicitation Number
2010-Q-12086
 
Point of Contact
Terren J. Grimble, Phone: 770-488-2487, Rafael A. Aviles, Phone: 770-488-2805
 
E-Mail Address
TGrimble@cdc.gov, raviles@cdc.gov
(TGrimble@cdc.gov, raviles@cdc.gov)
 
Small Business Set-Aside
N/A
 
Description
Sources Sought Ref# 2010-Q-12086 The Centers for Disease Control & Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Epidemiology and Strategic Information Branch, is seeking contractor sources with an understanding of the variety of laboratory assays that have been developed to estimate HIV incidence using cross-sectional data. The primary objectives of this project are: • To determine the proportion of samples from individuals in select populations in Eastern and Southern Africa with known HIV positive status of greater than 12 months that misclassify as recent infection on the assay (otherwise known as the "false-recent" rate). • To estimate assay-derived incidence using the observed false-recent rate in similar cross-sectional sites in Eastern and Southern Africa where the incidence assay(s) have been or will be applied. • To compare assay-derived incidence to other measures of incidence in the same population. Scope of Work There are ongoing cohort studies for HIV incidence in multiple sites in Africa to identify candidate sites for HIV prevention research among populations at risk for HIV infection. We propose to integrate incidence assay validation studies within these cohorts, particularly those in Eastern and Southern Africa for settings where false-recent rates have not been established (e.g. Ethiopia and Mozambique) but where assay-based incidence surveys have been conducted or currently being planned. Validation studies will: 1) quantify the level of misclassification among HIV-infected persons with > 12 months of infection on the various assays; 2) estimate assay-derived incidence in cross-sectional sites that are representative to the sample in which the false-recent rate is derived; 3) compare assay-based incidence to other measures of incidence (e.g. comparisons against directly observed incidence, other assays). Technical Requirements Task 1: Conduct a false recent calibration study for HIV-1 incidence assays to determine the percentage of false recent samples from individuals with known HIV positive status of greater than 12 month duration • Develop protocol incorporating a false recent calibration study at the site • Assist local staff to conduct data collection • Assist local laboratory staff to conduct incidence assay testing on entire sample of known long-term infections using: o BED capture enzyme immunoassay o New developmental assays (such as: the rIDR-M avidity index assay, the rIDR-M limiting antigen avidity assay, and the rapid incidence prevalence assay). • Assist local staff to conduct data analysis, including development of the local false-recent rate for HIV-1 incidence assays • Assist local staff to develop a draft report on findings Task 2: Estimate assay-derived incidence in a cross-sectional sample of HIV-infected persons at the study site and, where possible, compare to other measures of incidence (e.g. directly observed cohort incidence). • Develop protocol incorporating incidence estimation in a cross-sectional samples at the site or proxy population • Assist local laboratory staff to conduct incidence assay testing on a cross-sectional samples at the site or proxy populations using: o BED capture enzyme immunoassay o New developmental assays (such as: the rIDR-M avidity index assay, the rIDR-M limiting antigen avidity assay, and the rapid incidence prevalence assay) • Assist local staff to conduct data analysis for incidence estimation • Assist local staff to develop a draft report on findings Deliverables The following deliverables shall be delivered to the COTR: Description Copies Due Date Draft report 2 December 30, 2011 Final report 2 June 30, 2012 The base period of performance is July 1, 2010 to June 30, 2012. A one year (12 months) option period following the base period is possible. This notification is intended to provide the Government with information on the availibility of qualified sources for the requirement. Any interested companies are welcome to submit their ability to provide this requirement via e-mail to ibi9@cdc.gov. Please include reference number (2010-Q-12086). Please respond by Thursday, April 29, 2010.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2010-Q-12086/listing.html)
 
Place of Performance
Address: Eastern and Southern Africa, United States
 
Record
SN02123476-W 20100417/100415235522-770bf09be94ad298834ffd32ce2ae2e7 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2020, Loren Data Corp.